Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 13, 2007

Celgene Plugs $20M into PTC Therapeutics

  • Celgene will make a $20 million equity investment in PTC Therapeutics. In return, Celgene will gain the right to enter an exclusive research deal related to two oncology targets for the development of small molecules with PTC’s GEMS (gene expression modulation by small molecules) technology.

    If Celgene exercises this option, PTC may receive funding for research efforts and milestone payments per target. Celgene will receive exclusive worldwide rights and pay PTC royalties on net sales of any products.

    The GEMS platform identifies small molecules that modulate post-transcriptional control mechanisms. These compounds target processes that act through the untranslated regions of mRNA.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.